Pediatric Type 2 Diabetes Mellitus Workup

  • Author: Alba Morales Pozzo, MD; Chief Editor: Stephen Kemp, MD, PhD   more...
 
Updated: Apr 17, 2012
 

Approach Considerations

According to criteria established by the American Diabetes Association, testing for type 2 diabetes should be considered when a patient is overweight (eg, body mass index [BMI] at the 85th percentile for age and sex, weight at the 85th percentile, weight 120% of ideal for height) and any 2 of the following factors exist[34] :

  • Family history of type 2 diabetes in first-degree or second-degree relative
  • Minority race or ethnicity (eg, American Indian, black, Hispanic, Asian or Pacific Islander)
  • Signs of insulin resistance or conditions associated with insulin resistance (eg, acanthosis nigricans, hypertension dyslipidemia, PCOS)

Recommendations for screening are as follows:

  • Initial screening may begin at age 10 years or at onset of puberty if puberty occurs at a young age
  • Screening should be performed every 2 years.
  • A fasting plasma glucose test is the preferred screening study

In children who do not meet the criteria described above but in whom diabetes is highly suspected, clinical judgment should be applied. If clinical suspicion for diabetes is high but a fasting blood glucose level is normal (< 100 mg/dL), an oral glucose tolerance test should be considered as a more sensitive screening tool.

Because the onset of type 2 diabetes frequently precedes the diagnosis by several years, testing for end-organ effects of the disease is important. In addition, perform dilated eye examination for retinopathy shortly after diagnosis and yearly thereafter.

Next

Plasma Glucose and Other Tests

A random plasma glucose concentration of 200 mg/dL or greater in association with polyuria, polydipsia, or unexplained weight loss is diagnostic of diabetes.[31]

In an asymptomatic patient, a fasting (ie, no caloric intake for at least 8 h) plasma glucose value of 126 mg/dL or greater or a 2-hour plasma glucose value of 200 mg/dL or greater during an oral glucose tolerance test is also diagnostic of diabetes.[31]

Fasting C-peptide and insulin levels are usually elevated in type 2 diabetes. Autoimmune markers (glutamic acid decarboxylase [GAD] and islet cell antibodies) are usually negative in type 2 diabetes but are frequently present in type 1 diabetes.[31]

Previous
Next

Evaluation for Diabetic Nephropathy

Microalbuminuria is said to be present if urinary albumin excretion is 30 mg/24 h (equivalent to 20 µg/min with a timed specimen or 30 mg of albumin per gram creatinine with a random sample). Testing for albuminuria can be performed using 1 of 3 methods, as follows:

  • Measurement of the ACR in a random spot collection
  • A 24–hour collection for albumin and creatinine determinations, which allows for simultaneous measurement of creatinine clearance
  • Timed (eg, 4-h or overnight) collection
Previous
Next

Evaluation for Dyslipidemia

Obtain fasting lipid profile after stable glycemia has been achieved and every 2 years thereafter if normal. Optimal lipid levels for children with type 2 diabetes are as follows[35] :

  • Triglycerides optimal level - Less than 150 mg/dL
  • Low-density lipoprotein (LDL) optimal level - Less than 100 mg/dL
  • High-density lipoprotein (HDL) optimal level - More than 35 mg/dL
Previous
Proceed to Treatment & Management
 
 
Contributor Information and Disclosures
Author

Alba Morales Pozzo, MD  Associate Professor, Department of Pediatrics, Division of Endocrinology and Diabetes, University of Arkansas for Medical Sciences

Alba Morales Pozzo, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, Arkansas Medical Society, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Arlan L Rosenbloom, MD  Adjunct Distinguished Service Professor Emeritus of Pediatrics, University of Florida College of Medicine; Fellow of the American Academy of Pediatrics; Fellow of the American College of Epidemiology

Arlan L Rosenbloom, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Epidemiology, American Pediatric Society, Endocrine Society, Florida Pediatric Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London)  Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD  Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Jean-Claude DesMangles, MD,to the development and writing of the source article.

References

  1. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. Jul 2004;27(7):1798-811. [Medline].

  2. Morales AE, Rosenbloom AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. J Pediatr. Feb 2004;144(2):270-3. [Medline].

  3. Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab. Jun 2004;89(6):2526-39. [Medline].

  4. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. Nov 2003;26(11):2999-3005. [Medline].

  5. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. Sep 1999;104(6):787-94. [Medline].

  6. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. Apr 1998;15(4):297-303. [Medline].

  7. Gungor N, Arslanian S. Progressive beta cell failure in type 2 diabetes mellitus of youth. J Pediatr. May 2004;144(5):656-9. [Medline].

  8. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. Feb 1999;22(2):345-54. [Medline].

  9. Wei JN, Sung FC, Li CY, et al. Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in taiwan. Diabetes Care. Feb 2003;26(2):343-8. [Medline].

  10. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care. May 1995;18(5):611-7. [Medline].

  11. Young TK, Martens PJ, Taback SP, et al. Type 2 diabetes mellitus in children: prenatal and early infancy risk factors among native canadians. Arch Pediatr Adolesc Med. Jul 2002;156(7):651-5. [Medline].

  12. Mayer-Davis EJ, Dabelea D, Lamichhane AP, D'Agostino RB Jr, Liese AD, Thomas J. Breast-feeding and type 2 diabetes in the youth of three ethnic groups: the SEARCh for diabetes in youth case-control study. Diabetes Care. Mar 2008;31(3):470-5. [Medline].

  13. Type 2 diabetes in children and adolescents. American Diabetes Association. Pediatrics. Mar 2000;105(3 Pt 1):671-80. [Medline].

  14. Dabelea D, Bell RA, D'Agostino RB Jr, et al. Incidence of diabetes in youth in the United States. JAMA. Jun 27 2007;297(24):2716-24. [Medline].

  15. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. Aug 2005;28(8):1876-81. [Medline].

  16. Ehtisham S, Hattersley AT, Dunger DB, Barrett TG,. First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child. Jun 2004;89(6):526-9. [Medline].

  17. Kadiki OA, Reddy MR, Marzouk AA. Incidence of insulin-dependent diabetes (IDDM) and non-insulin-dependent diabetes (NIDDM) (0-34 years at onset) in Benghazi, Libya. Diabetes Res Clin Pract. May 1996;32(3):165-73. [Medline].

  18. Chan JC, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS. Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad Med J. Mar 1993;69(809):204-10. [Medline].

  19. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Type 2 diabetes in Asian-Indian urban children. Diabetes Care. Apr 2003;26(4):1022-5. [Medline].

  20. Sayeed MA, Hussain MZ, Banu A, Rumi MA, Azad Khan AK. Prevalence of diabetes in a suburban population of Bangladesh. Diabetes Res Clin Pract. Jan 1997;34(3):149-55. [Medline].

  21. Braun B, Zimmermann MB, Kretchmer N, Spargo RM, Smith RM, Gracey M. Risk factors for diabetes and cardiovascular disease in young Australian aborigines. A 5-year follow-up study. Diabetes Care. May 1996;19(5):472-9. [Medline].

  22. McGrath NM, Parker GN, Dawson P. Early presentation of type 2 diabetes mellitus in young New Zealand Maori. Diabetes Res Clin Pract. Mar 1999;43(3):205-9. [Medline].

  23. Eppens MC, Craig ME, Jones TW, Silink M, Ong S, Ping YJ. Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care and complications. Curr Med Res Opin. May 2006;22(5):1013-20. [Medline].

  24. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. May 2000;136(5):664-72. [Medline].

  25. Grinstein G, Muzumdar R, Aponte L, et al. Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res. 2003;60(3):121-6. [Medline].

  26. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. Jul 26 2006;296(4):421-6. [Medline].

  27. Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. Jul 2000;58(1):302-11. [Medline].

  28. Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. Oct 2007;30(10):2593-8. [Medline].

  29. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High Burden of Kidney Disease in Youth-Onset Type 2 Diabetes. Diabetes Care. Mar 19 2012;[Medline].

  30. Krakoff J, Lindsay RS, Looker HC, et al. Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care. Jan 2003;26(1):76-81. [Medline].

  31. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. Mar 2000;23(3):381-9. [Medline].

  32. Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. Mar 2002;87(3):1017-23. [Medline].

  33. Pinhas-Hamiel O, Standiford D, Hamiel D, et al. The type 2 family: a setting for development and treatment of adolescent type 2 diabetes mellitus. Arch Pediatr Adolesc Med. Oct 1999;153(10):1063-7. [Medline].

  34. [Guideline] Diagnosis and classification of diabetes mellitus. Diabetes Care. Jan 2004;27 Suppl 1:S5-S10. [Medline].

  35. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care. Jul 2003;26(7):2194-7. [Medline].

  36. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. May 3 2011;154(9):602-13. [Medline].

  37. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. May 3 2011;154(9):602-13. [Medline].

  38. [Best Evidence] Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Parkkari J, et al. Effect of long-term endurance and strength training on metabolic control and arterial elasticity in patients with type 2 diabetes mellitus. Am J Cardiol. Apr 1 2009;103(7):972-7. [Medline].

  39. McGavock J, Sellers E, Dean H. Physical activity for the prevention and management of youth-onset type 2 diabetes mellitus: focus on cardiovascular complications. Diab Vasc Dis Res. Dec 2007;4(4):305-10. [Medline].

  40. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. Dec 12 2006;114(24):2710-38. [Medline].

  41. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. Aug 2004;114(2 Suppl 4th Report):555-76. [Medline].

  42. [Guideline] Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Feb 2011;42(2):517-84. [Medline].

  43. [Best Evidence] International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. Jul 2009;32(7):1327-34. [Medline]. [Full Text].

  44. US Food and Drug Administration. Early Communication About Safety of Lantus (insulin Glargine). [Full Text].

  45. [Best Evidence] Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. Mar 23 2009;169(6):616-25. [Medline].

  46. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. Jul 5 2007;357(1):28-38. [Medline].

  47. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf. Jul 2007;16(7):711-25. [Medline].

  48. [Best Evidence] Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. Jun 20 2009;373(9681):2125-35. [Medline].

 
Previous
Next
 
Simplified scheme for the pathophysiology of type 2 diabetes mellitus.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.